CD274 and neoplasm: Although tumor mutation burden (TMB), PD-L1 expression, tumor immune microenvironment (TIME), and some specific gene mutations have been reported to be associated with ICI response (5–9), only a few of them have been validated in the clinic and even those validated biomarkers still had their limitations.